23.70 USD
+0.20
0.85%
At close Mar 28, 4:00 PM EDT
After hours
23.72
+0.02
0.08%
1 day
0.85%
5 days
2.38%
1 month
0.42%
3 months
11.90%
6 months
2.46%
Year to date
11.37%
1 year
10.44%
5 years
-11.90%
10 years
-11.90%
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

16% more first-time investments, than exits

New positions opened: 124 | Existing positions closed: 107

6% more repeat investments, than reductions

Existing positions increased: 398 | Existing positions reduced: 376

0.56% more ownership

Funds ownership: 99.72% [Q3] → 100.28% (+0.56%) [Q4]

0% less funds holding

Funds holding: 988 [Q3] → 987 (-1) [Q4]

7% less capital invested

Capital invested by funds: $44.1B [Q3] → $41B (-$3.06B) [Q4]

17% less call options, than puts

Call options by funds: $166M | Put options by funds: $199M

36% less funds holding in top 10

Funds holding in top 10: 14 [Q3] → 9 (-5) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$21
11%
downside
Avg. target
$24
2%
upside
High target
$29
22%
upside

7 analyst ratings

positive
29%
neutral
71%
negative
0%
Barclays
Lauren Lieberman
48% 1-year accuracy
47 / 97 met price target
3%downside
$23
Equal-Weight
Maintained
27 Mar 2025
Evercore ISI Group
Javier Escalante
50% 1-year accuracy
1 / 2 met price target
5%upside
$25
In-Line
Initiated
24 Mar 2025
Canaccord Genuity
Susan Anderson
29% 1-year accuracy
11 / 38 met price target
22%upside
$29
Buy
Maintained
5 Mar 2025
Piper Sandler
Korinne Wolfmeyer
20% 1-year accuracy
9 / 46 met price target
14%upside
$27
Overweight
Maintained
24 Feb 2025
UBS
Peter Grom
48% 1-year accuracy
11 / 23 met price target
11%downside
$21
Neutral
Maintained
7 Feb 2025

Financial journalist opinion

Based on 16 articles about KVUE published over the past 30 days

Positive
Seeking Alpha
12 hours ago
Buy 3 'Safer' Dividend Kings Of 25 From March's 55
The article highlights 55 Dividend Kings, noting that five of the top ten by yield offer annual dividends from a $1K investment exceeding their single share prices. Analysts predict top-ten Kingly net gains ranging from 12.57% to 50.26% for March 2026, with six out of ten top-yield Kings expected to be top gainers. Sixteen out of fifty-five Kings show negative free cash flow margins, making them cash-poor and unsafe to buy; focus on safer Kings like Altria, United Bankshares, and Hormel.
Buy 3 'Safer' Dividend Kings Of 25 From March's 55
Positive
24/7 Wall Street
2 days ago
Tariffs Could Keep the Federal Reserve on Hold: 5 High-Yield Dividend Kings Are Our Top Calls
High-yield dividend stocks are a favorite among investors for good reason.
Tariffs Could Keep the Federal Reserve on Hold: 5 High-Yield Dividend Kings Are Our Top Calls
Positive
Seeking Alpha
1 week ago
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
2025 Dividend Kings: Strong Run Continues
Neutral
Business Wire
1 week ago
Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey
SUMMIT, N.J.--(BUSINESS WIRE)--Today, Kenvue Inc. (NYSE: KVUE) held a ribbon-cutting ceremony for its new 290,000 sq. ft. global headquarters in Summit, New Jersey.
Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey
Positive
Seeking Alpha
2 weeks ago
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high dividends. These are exactly the resilient defensive stocks in an un-loved healthcare sector that investors are now piling into as the VIX spikes.
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Positive
Seeking Alpha
2 weeks ago
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, with dividends from $1K invested meeting or exceeding their single share prices.
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
Neutral
24/7 Wall Street
2 weeks ago
Recession Could Be Coming: 5 Strong Buy High-Yield Dividend Stocks That Will Still Outperform
The last time the economy experienced two negative quarters of gross domestic product was the first and second quarters of 2022, with a 1.6% pullback in the first quarter and a 0.6% decline in the second.
Recession Could Be Coming: 5 Strong Buy High-Yield Dividend Stocks That Will Still Outperform
Neutral
Business Wire
3 weeks ago
Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry.
Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
Neutral
CNBC Television
3 weeks ago
Faber Report: Kenvue settles proxy fight with activist Starboard
CNBC's David Faber breaks down the latest news on Kenvue.
Faber Report: Kenvue settles proxy fight with activist Starboard
Positive
Reuters
3 weeks ago
Kenvue settles proxy fight with activist Starboard, appoints three directors
Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.
Kenvue settles proxy fight with activist Starboard, appoints three directors
Charts implemented using Lightweight Charts™